CN102665753A - 诊断或预测hcv感染的患者中丙型肝炎后果的方法 - Google Patents

诊断或预测hcv感染的患者中丙型肝炎后果的方法 Download PDF

Info

Publication number
CN102665753A
CN102665753A CN2010800436612A CN201080043661A CN102665753A CN 102665753 A CN102665753 A CN 102665753A CN 2010800436612 A CN2010800436612 A CN 2010800436612A CN 201080043661 A CN201080043661 A CN 201080043661A CN 102665753 A CN102665753 A CN 102665753A
Authority
CN
China
Prior art keywords
experimenter
hepatitis
polymorphism
interferon
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800436612A
Other languages
English (en)
Chinese (zh)
Inventor
P-Y·博丘德
A·劳赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
Centre Hospitalier Universitaire Vaudois CHUV
Original Assignee
Universitaet Bern
Centre Hospitalier Universitaire Vaudois CHUV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern, Centre Hospitalier Universitaire Vaudois CHUV filed Critical Universitaet Bern
Publication of CN102665753A publication Critical patent/CN102665753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800436612A 2009-07-31 2010-07-09 诊断或预测hcv感染的患者中丙型肝炎后果的方法 Pending CN102665753A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH12012009 2009-07-31
CH01201/09 2009-07-31
US28253810P 2010-02-26 2010-02-26
US61/282,538 2010-02-26
PCT/IB2010/053139 WO2011013019A1 (en) 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients

Publications (1)

Publication Number Publication Date
CN102665753A true CN102665753A (zh) 2012-09-12

Family

ID=42727569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800436612A Pending CN102665753A (zh) 2009-07-31 2010-07-09 诊断或预测hcv感染的患者中丙型肝炎后果的方法

Country Status (10)

Country Link
US (1) US20110165124A1 (enExample)
EP (1) EP2459210A1 (enExample)
JP (1) JP2013500713A (enExample)
KR (1) KR20120040725A (enExample)
CN (1) CN102665753A (enExample)
AU (1) AU2010277239A1 (enExample)
BR (1) BR112012001931A2 (enExample)
CA (1) CA2768772A1 (enExample)
MX (1) MX2012001058A (enExample)
WO (1) WO2011013019A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108220424A (zh) * 2018-02-05 2018-06-29 广州和康医疗技术有限公司 一种检测il28基因位点的方法及试剂盒

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656159B2 (ja) * 2009-08-24 2015-01-21 独立行政法人理化学研究所 インターフェロン療法の効果予測用マーカー
RU2567806C2 (ru) * 2009-12-22 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Усиление прогностической ценности полиморфизма гена il28b в комбинации с количественной оценкой ip-10 в сыворотке при ответе на пегинторферон и рибавирин по сравнению с каждым из этих биомаркеров в отдельности
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
EP2691094A1 (en) * 2011-03-31 2014-02-05 Novartis AG Alisporivir to treat hepatitis c virus infection
EP2726632A1 (en) * 2011-06-30 2014-05-07 Centre Hospitaller Universitaire Vaudois (CHUV) Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
MX2014001355A (es) 2011-08-03 2014-11-21 Cytheris Inmunoterapia contra el vhc.
JP2013074888A (ja) * 2011-09-15 2013-04-25 Arkray Inc ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法
US20140271542A1 (en) * 2011-10-05 2014-09-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Service Genetic marker for predicting prognosis in patients infected with hepatitis c virus
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104540849B (zh) 2012-03-28 2020-07-28 美利坚合众国,由健康及人类服务部部长代表 分离的蛋白、分离的核酸分子及其用途
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299094A1 (en) * 2004-07-01 2008-12-04 Medical Research Fund Of Tel Aviv Methods and Kits for Predicting Liver Fibrosis Progression Rate in Chronic Hepatitis C Patients

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001050A (en) 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1997001603A1 (en) 1995-06-26 1997-01-16 Henkel Corporation Methods of preparing inorganic pigment dispersions
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
DE69940430D1 (de) 1998-06-24 2009-04-02 Illumina Inc Dekodierung von matrixartig-angeordneten Sensoren durch Mikropartikel
GB9817266D0 (en) 1998-08-07 1998-10-07 Imperial College Method
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc Ｃ型肝炎ウイルス感染者の経過に関する遺伝子およびその利用
CA2735439A1 (en) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
CN102459647B (zh) * 2009-05-21 2015-05-06 默沙东公司 与干扰素-α应答有关的遗传标记

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299094A1 (en) * 2004-07-01 2008-12-04 Medical Research Fund Of Tel Aviv Methods and Kits for Predicting Liver Fibrosis Progression Rate in Chronic Hepatitis C Patients

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STEPHAN BRAND，ET AL: "IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression", 《AM J PHYSIOL GASTROINTEST LIVER PHYSIOL》 *
UNKNOWN: "ss66661174", 《PUBMED SNP》 *
WJ JORDAN，ET AL: "Human interferon lambda-1 (IFN-l1/IL-29) modulates the Th1/Th2 response", 《GENES AND IMMUNITY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108220424A (zh) * 2018-02-05 2018-06-29 广州和康医疗技术有限公司 一种检测il28基因位点的方法及试剂盒

Also Published As

Publication number Publication date
US20110165124A1 (en) 2011-07-07
EP2459210A1 (en) 2012-06-06
CA2768772A1 (en) 2011-02-03
KR20120040725A (ko) 2012-04-27
BR112012001931A2 (pt) 2017-07-18
JP2013500713A (ja) 2013-01-10
AU2010277239A1 (en) 2012-02-02
MX2012001058A (es) 2012-06-19
WO2011013019A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
CN102665753A (zh) 诊断或预测hcv感染的患者中丙型肝炎后果的方法
Promrat et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C
Abe et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy
Idrees Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan
Serajee et al. Polymorphisms in xenobiotic metabolism genes and autism
CN104774933A (zh) 用于检测人il28b基因多态性的引物、试剂盒及方法
Sarrazin Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance
Tokita et al. Influence of TT virus on the histopathological features of nonalcoholic fatty liver disease
WO2011146985A1 (en) Method of determining response to treatment with immunomodulatory composition
Hayashi et al. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg‐interferon and ribavirin therapy
Abe et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state
JP2023552199A (ja) コロナウイルス感染症を発症するリスクが高い対象を特定する方法及びその治療法
Neukam et al. Different distributions of hepatitis C virus genotypes among HIV‐infected patients with acute and chronic hepatitis C according to interleukin‐28B genotype
US20140154209A1 (en) Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
US20140271542A1 (en) Genetic marker for predicting prognosis in patients infected with hepatitis c virus
JP4295955B2 (ja) インターフェロンαレセプター２型遺伝子の多型およびその使用
Hiramine et al. A thymine–adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus
WO2003102181A1 (fr) Procede de detection de polymorphisme genique
Shi et al. Application of kinetic polymerase chain reaction and molecular beacon assays to pooled analyses and high‐throughput genotyping for candidate genes
CN103710447B (zh) 一种预测强直性脊柱炎易感性的方法和试剂
US6656691B2 (en) TCF-1 nucleotide sequence variation
WO2013030786A1 (en) Method for diagnosing or predicting hepatocellular carcinoma outcome
CN106834449A (zh) 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
CN106834448A (zh) 与原发性胆汁性胆管炎关联的白细胞介素16及其应用
CN106755461A (zh) 与原发性胆汁性胆管炎关联的白细胞介素21及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176284

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120912

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1176284

Country of ref document: HK